Medical Policy and Coding Updates - December 2022
Summary
Botulinum toxin codes J0585, J0586, J0587 and J0588 require review for medical necessity and prior authorization for dates of service starting on and after December 1, 2022, under the temporomandibular joint disorder and hyperhidrosis policies. Coding changes effective December 1, 2022 also set C9142 to require medical necessity review, changed J0172 to require investigational review with prior authorization still required, and removed medical necessity review for A9593, A9594, A9595, A9596 and A9800. Drug policy updates added Botox, Dupixent for prurigo nodularis, Sotyktu for plaque psoriasis, and Vegzelma and Alymsys in the VEGF inhibitor policy.
Get alerts when payers change rules like this one
We check Premera Blue Cross and other payers every day and email you when a change matches your specialty and state.